How Lingo Partnership Will Impact Abbott Stock (ABT)

• Abbott Laboratories recently announced an exclusive partnership with Berry Street that pairs its Lingo over the counter glucose monitor with insurance covered virtual nutrition coaching, while its Volt Pulsed Field Ablation System recorded first clinical use in both Canada and at UnityPoint Health in the US for atrial fibrillation procedures.
• This combination of consumer focused metabolic tracking through Lingo and expanding Volt PFA procedure use in electrophysiology reflects Abbott Laboratories advancing its device and wellness pipeline across both everyday health decisions and complex cardiac care.
• We will now look at how Abbott Laboratories' investment narrative could be influenced by the Lingo and Berry Street collaboration.

See how Abbott Laboratories fits into the broader health and medtech story by comparing it with a curated group of list of solid balance sheet and fundamentals (23 results) that may appeal to long-term, fundamentals-focused investors.

Abbott Laboratories Investment Narrative Recap

To own Abbott Laboratories, you need to believe its medical devices, diagnostics and Nutrition arms can keep turning product launches into steadier earnings, even as legal and cost headwinds persist. The Lingo and Berry Street collaboration fits that view by pushing Abbott Laboratories further into everyday, subscription like health use cases. The more immediate operational swing factor still sits in margin rebuild across the portfolio, not this single partnership.

The biggest risk today remains Nutrition legal and regulatory exposure, with the recent infant formula settlement adding to an already heavy cost bill and keeping pressure on profitability. In that context, the new consumer wellness and Volt PFA updates are helpful for the long term narrative but do not materially change the near term earnings risk from any further actions or compliance spending.

The Berry Street partnership around Lingo looks most relevant here because it ties directly into Abbott Laboratories broader glucose monitoring and metabolic health push. Lingo targets non insulin users and sits alongside expectations for wider CGM adoption, including potential Medicare coverage for similar populations. Operationally, it supports the idea of a larger addressable base for Abbott Laboratories sensor technology.

Execution will hinge on how effectively Lingo users convert into recurring hardware and coaching usage, and whether data from this over the counter product feeds into Abbott Laboratories wider diabetes and diagnostics ecosystem. For investors watching catalysts, Lingo plus Berry Street is another proof point that Abbott Laboratories is trying to extend glucose tracking beyond traditional diabetes care, while still needing to fund that expansion alongside settlements, high debt levels and ongoing manufacturing investments.

What The Lingo Partnership Means For Abbott Laboratories' Forecasts

Abbott Laboratories' narrative projects US$60.0b revenue and US$9.6b earnings by 2029. This assumes 8.8% yearly revenue growth and an earnings increase of about US$4.2b from US$5.4b today.

Uncover why Abbott Laboratories' fair value indicates a 19% potential upside to its current price before that gap begins to close.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community cluster between about US$81 and US$120 per share, so some members see Abbott Laboratories as close to fully priced while others flag meaningful upside. Consider this in the context of ongoing Nutrition legal exposure and the Lingo and Volt updates, then decide which storyline you find more persuasive and explore the full range of views.

Explore 5 other Abbott Laboratories fair value estimates, including one that suggests as much as 20% downside from the current price.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Abbott Laboratories. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Looking For More Investment Ideas Beyond Abbott Laboratories?

If Abbott Laboratories has sharpened your appetite for high quality healthcare and medtech exposure, it can be useful to scan a broader watchlist that fits your preferred mix of balance sheet strength, income potential and risk level.

• For investors who care most about resilient businesses and capital preservation, consider a 31 resilient stocks with low risk scores that have historically paired steadier fundamentals with lower volatility profiles.
• If the goal is long term compounding from strong financial footing, a list of solid balance sheet and fundamentals (23 results) can help you focus on companies that carry manageable debt and robust cash generation.
• Income seekers can look for reliable cash distributions by reviewing a 7 dividend fortresses that may suit a portfolio built around regular payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com